We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

According to IQVIATM (IMS Health), Levetiracetam in Sodium Chloride Injection had US sales of approximately $19 million for the 12-month period ending November 2024. Caplin Point Laboratories is a ...

That said, it's worth pointing out that Novo Nordisk stock is now down an astonishing 44% from its all-time high hit back in July. At a price-to-earnings ratio now approaching 28, and with most ...

Bagsværd, Denmark, 17 January 2025 - Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial ...

15 new drugs selected for negotiation accounted for $41 billion in Medicare Part D costs between 2023 and 2024. Medicare beneficiaries are projected to save $7.2 billion annually from the $2,000 ...

Investing.com -- Shares of Novo Nordisk (NYSE:NVO) fell 3.6% on Friday after the U.S. Department of Health and Human Services (HHS) announced that Ozempic and Wegovy are among 15 medications ...

The Centers for Medicare and Medicaid Services (CMS) released its second round of drug negotiation targets, a list of 15 drugs under Medicare Part D, including Novo Nordisk's (NVO) blockbuster GLP-1s.

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is rolling out new data on a higher-dose injection in obesity. In the phase 3b ...

Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence Novo Nordisk A/S Fri, Jan 17, 2025, 7:11 AM 5 min read ...

Novo Nordisk said that patients taking a higher dose of its blockbuster obesity drug Wegovy lost more weight than those on a lower dose without experiencing an increase in side-effects ...

The Centers for Medicare and Medicaid Services (CMS) released its second round of drug negotiation targets, a list of 15 drugs under Medicare Part D, including Novo Nordisk's (NVO) blockbuster GLP-1s.